Open, Single Arm,Multicenter Phase 2 Clinical Study to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for CD19 Positive Lymphoma

Trial Profile

Open, Single Arm,Multicenter Phase 2 Clinical Study to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for CD19 Positive Lymphoma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms EECPL
  • Sponsors Sinobioway Cell Therapy
  • Most Recent Events

    • 06 Apr 2017 New trial record
    • 21 Mar 2017 Planned Initiation date has been changed from 1 Mar 2017 to 1 Apr 2017.
    • 21 Mar 2017 Status has been changed from recruiting to not yet recruiting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top